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Summary 
Tau is abundant in the axon, whereas MAP2 is found 
in the cell body and dendrites. To understand their 
differential localization, we performed transfection 
studies on primary cultured neurons using tagged tau, 
MAP2, MAP2C, and their chimeric/deletion mutants. 
We found that MAP2 was prevented from entering the 
axon by its N-terminal projection domain and that mi- 
crotubule binding of tau was stronger in the axon than 
in the cell body and dendrites, whereas that of MAP2/ 
MAP2C was tighter in the cell body and dendrites than 
in the axon. These binding properties were determined 
by their microtubule-binding domains and were sug- 
gested to be regulated by phosphorylation, at least in 
the case of tau. Thus, the suppressed axonal transit of 
MAP2 and locally regulated microtubule binding may 
play important roles for their sorting in neurons. 
Introduction 
Microtubules are one of the main cytoskeletal elements 
in all eukaryotic ells and are particularly abundant in neu- 
ronal cells. It is well known that there are several kinds 
of associated proteins that regulate the structure and dy- 
namics of microtubules. Among these proteins, tau and 
microtubule-associated protein 2 (MAP2) are the major 
species in neuronal tissues, which are flexible, rod-like 
structures, form arm-like projections on microtubules, and 
have been identified as the components of crossbridges 
found in the microtubule domain in neurons (Murphy and 
Borisy, 1975; Weingarten et al., 1975; Cleveland et al., 
1977a, 1977b; Kim et al., 1979; Zingsheim et al., 1979; 
Hirokawa, 1982, 1991; Voter and Erickson, 1982; OIm- 
sted, 1986; H irokawa et al., 1988a, 1988b). Recent cloning 
studies revealed that tau and MAP2 share a homologous 
microtubule-binding domain in their C-terminal halves 
(Figure 1) (Aizawa et al., 1988; Lee et al., 1988; Lewis et 
al., 1988), and when they are transfected into nonneuronal 
cells, they form bundles of microtubules that show struc- 
tures very similar to those found in neurons (Kanai et al., 
1989; Lewis et al., 1989; Knops et al., 1991 ; Chen et al., 
1992). 
However, tau and MAP2 are found in different regions 
in neurons immunocytochemically; tau is abundant in the 
axon (Binder et al., 1985; Kosik and Finch, 1987), whereas 
MAP2 is localized in the cell body and dendrites (Bernhardt 
and Matus, 1984) (Figure 2). It is therefore of major impor- 
tance to clarify the mechanism for their different Iocaliza- 
tions in order to understand neural polarity. Concerning 
this mechanism, two possibilities have been proposed. 
One is that their Iocalizations are determined by where 
they are expressed, as tau m RNA spread into the proximal 
portion of axon while MAP2 m RNA extended into dendrites 
(Garner et al., 1988; Litman et al., 1993). The other is that 
locally differing protein turnover generates their selective 
localization. When MAP2 was injected into neurons, it was 
degradated more rapidly in the axon than in the cell body 
and dendrites (Okabe and Hirokawa, 1989). However, 
complete understanding is still to be attained. 
Here, we propose new mechanisms regarding this ques- 
tion by transfecting primary cultured neurons with tagged 
cDNAs encoding tau, MAP2, MAP2C (juvenile form of 
MAP2), and their chimeric/deletion mutants (Figure 1). 
MAP2 and the mutants containing its N-terminal projection 
domain were transported along the axon much shorter 
distances than others, suggesting that the N-terminal pro- 
jection domain of MAP2 suppressed its axonal transit. As 
for their subcellular microtubule binding, tau bound to mi- 
crotubules more strongly in the axon than in the cell body 
and dendrites, whereas MAP2/MAP2C bound to microtu- 
bules more tightly in the cell body and dendrites, and their 
locally selective bindings were determined by their C-ter- 
minal microtubule-binding domains. Interestingly, tau in 
the cell body and dendrites was mostly phosphorylated 
at the TAU-1 site (Binder et al., 1985; Papasozomenos 
and Binder, 1987; Hasegawa et al., 1992; Szendrei et al., 
1993), suggesting that microtubule binding may be regu- 
lated by local phosphorylation/dephosphorylation, at least 
in the case of tau. Thus, suppressed transit of MAP2 into 
the axon and the locally regulated microtubule binding of 
tau and MAP2/MAP2C may play important roles for their 
differential ocalization in neurons. 
Results 
Distribution of Native Tau, MAP2, and MAP2C in 
Primary Cultured Spinal Cord Neurons 
To investigate the distribution of native tau, MAP2, and 
MAP2C in primary cultured spinal cord neurons, we fixed 
and immunostained the cells 17 days after plating, as cells 
in our transfection studies were transfected 12 days after 
plating and then fixed 5 days later. TAU-1, a monoclonal 
anti-tau antibody, stained axons, whereas affinity-purified 
polyclonal anti-MAP2 antibody detected high molecular 
weight MAP2 in cell body and dendrites but not in axons 
(Figures 2a-2c). Because "I'AU-1 detects only the dephos- 
phorylated form of tau at the TAU-1 site, we treated the 
culture with alkaline phosphatase and stained tau with 
TAU-1 (see Figure 4d) (Papasozomenos and Binder, 
1987). TAU-1 stained, though weakly, the cell body and 
proximal dendrites in addition to the axon, suggesting that 
tau phosphorylated at the TAU-1 site is localized in the 
cell body and proximal dendrites in smaller amounts in 
this stage of culture. MAP2C is an alternatively spliced 
isoform of MAP2 and is reported to be observed in cell 
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Figure 1. Constructs Used in This Study 
(A) Diagram of the constructs of tau, MAP2, MAP2C, and their mutants. 
Tau, MAP2, and MAP2C are full-length MAPs. Tau-MAP2, MAP2- 
Tau, and MAP2C-Tau are chimeric mutants (e.g., Tau-MAP2 contains 
the N-terminal projection domain of tau, fused to the C-terminal micro- 
tubule-binding domain of MAP2). Tau(N), MAP2(N), and MAP2C(N) are 
deletion mutants containing only their N-terminal projection domains 
(e.g., Tau(N) has the N-terminal domain of tau but lacks the C-terminal 
microtubule-binding domain). Tau(MT) and MAP2(MT) are also dele- 
tion mutants and consist of the C-terminal microtubule-binding do- 
mains (e.g., Tau(MT) contains only the C-terminal half of tau without 
its N-terminal projection domain). Boxed regions (three or four parts) 
are the repeated microtubule-binding motifs, and open and shaded 
portions are derived from tau and MAP2 (MAP2C), respectively. 
(B) Amino acid comparison between tau and MAP2 (MAP2C) in the 
C-terminal microtubule-binding domain, which is composed of the pro- 
line-rich region, three or four repeated domains, and the C-terminal 
acidic region (numbering according to rat tau [Kanai et al., 1989] and 
mouse MAP2 [Lewis et al., 1988]). The percentages of identical amino 
acids between tau and MAP2 are 50% (proline-rich region), 63% (re- 
peat 1), 74% (repeat 3), 63% (repeat 4), and 65% (C-terminal acidic 
region). The TAU-1 site is underlined in the proline-rich region (GERS- 
GYSSPGSPGTPG; Szendrei et al., 1993). Note that there are several 
Ser(Thr) residues followed by a Pro in this microtubule-binding domain, 
especially in the TAU-1 site. 
bodies, dendrites, and axons of developing neurons 
(Tucker et al., 1988a, 1988b). As an antibody against only 
MAP2C (which does not stain MAP2) was not available, we 
performed a double staining using two types of anti-MAP2 
antibodies: HM-2, a monoclonal antibody that recognizes 
both MAP2 and MAP2C, and a polyclonal antibody that 
stains only MAP2 (Figure 2a). However, the staining pat- 
terns of both antibodies showed few differences, if any 
(data not shown), and we could not detect MAP2C in the 
axon by immunofluorescence microscopy in this stage of 
neurons. 
Construction of Tagged cDNAs Encoding Tau, 
MAP2, MAP2C, and Chimeric/Deletion Mutants 
Although tau and MAP2 (MAP2C) consist of the N-terminal 
projection domain and the homologous C-terminal micro- 
tubule-binding domain, tau is abundant in the axon while 
MAP2 is localized in the cell body and dendrites. To study 
the mechanisms for their different subcellular Iocalizations 
in neurons, we performed a series of transfection studies 
into mouse primary cultured spinal cord neurons using 
cDNAs encoding tau (the largest isoform, 432 amino acids; 
Kanai et al., 1989, 1992), MAP2 (1828 amino acids; Lewis 
et al., 1989), MAP2C (juvenile type of MAP2, 467 amino 
acids; Papandrikopoulou et al., 1989; Umeyama et al., 
1993), and their chimeric/deletion mutants (Figure 1). As 
neurons also express these MAPs in nature, we must dis- 
tinguish the transfectants from the intrinsic MAPs. Tau 
and MAP2 share a homologous C-terminal microtubule- 
binding domain (Aizawa et al., 1988; Lee et al., 1988; 
Goedert et al., 1989; Kanai et al., 1989; Kosik et al., 1989; 
Lewis et al., 1989; Papandrikopoulou et ai., 1989), and 
the C-terminal tail of tau and MAP2C has little effect on 
microtubule binding and bundling (Kanai et al., 1992; 
Umeyama et al., 1993); in contrast, their N-terminal projec- 
tions could participate in possible antiparallel dimerization 
(Steiner et al., 1990; Chen et al., 1992; Kanai et al., 1992; 
Wille et al., 1992a, 1992b, 1992c). Therefore, we intro- 
duced a short sequence from c-myc (KLISEEDL; Evan et 
al., 1985; Wong and Cleveland, 1990; Meichsner et al., 
1993) or c-myb (EDPEKEKRIKEL) to their C-terminal tail 
as a tag. As we use the antibodies against c-myc and 
c-myb sequences in this study, we checked these antibod- 
ies and found that they did not stain the control primary 
cultured spinal cord cells (data not shown). 
Because primary cultured spinal cord neurons grow on 
a sheet of glial cells, it is very important to use a high 
expression, neu ton-specific vector system in order to per- 
form the transfection studies on this culture. At the time of 
transfection, 12 clays after plating, glial cells had become 
confluent, suggesting that their requirement for additional 
actin was low, whereas neurons might still spread their 
processes as if more actin proteins were necessary for 
them. Then, we compared the expression levels of 13-actin 
mRNA between neurons and glial cells by in situ hybridiza- 
tion, which revealed that the 13-actin expression level was 
very high in neurons but very low in glial cells (Figure 2d). 
Therefore, we chose a ~-actin promoter, and the con- 
structs were inserted into a I?,-actin enhancer-driven pins- 
mid (Xie, 1984; Kanai et al., 1989, 1992) for the following 
transfection experiments. 
To check the microtubule-binding and -bundling abilities 
of the tagged MAPs, we transfected them into a mouse 
fibroblast cell line, L cells. They bound to and bundled 
microtubules like native MAPs transfected into L cells, 
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Figure 2. Distribution of Native Tau and MAP2 in Primary Cultured 
Spinal Cord Neurons 
(a) Immunoblots of brain whole homogenates from postnatal day 0 
suggesting that their microtubule-binding and -bundling 
abilities were intact (data not shown; Kanai et al., 1989, 
1992; Lewis et al., 1989; Umeyama et al., 1993). 
Transfect ion of Tagged Tau, MAP2, and MAP2C into 
Primary Cultured Neurons 
Mouse primary cultured spinal cord neurons were trans- 
fected with tagged tau, MAP2, and MAP2C (c-myc). To 
determine the culture period after transfection, we per- 
formed time course studies and fixed the cells at 2, 5, 8, 
or 11 days after transfection. As the distribution patterns 
of exogenous MAPs in neurons did not change during this 
period, cells were fixed 5 days after transfection in the 
following experiments (data not shown). 
First, to investigate the subcellular distribution of trans- 
fected MAPs, we fixed the cells without detergent extrac- 
tion (Figure 3). Tau and MAP2C were stained far into the 
axon (tau, 878 _+ 333 i~m, n = 22; MAP2C, 600 _ 132 I~m, 
n = 16) as well as strongly in the cell body and dendrites 
(Figures 3a and 3b). However, although MAP2 was de- 
tected strongly in the cell body and dendrites, it was found 
only in the short proximal segment of the axon (MAP2, 
22.7 _ 31.0 I~m, n = 29; Figure 3c). As it is very difficult 
to identify the axon of a MAP2-transfected neuron, and 
to exclude the possibility that differing expression levels 
between tau and MAP2 influence their axonal entries, we 
performed a pair of cotransfection studies using tau 
(c-myc)/MAP2(c-myb) and tau(c-myb)lMAP2(c-myc) to ex- 
press exogenous tau and MAP2 in the same neurons, 
equalizing their expression levels by changing their DNA 
ratio (see Experimental Procedures). In each case, tau was 
found far into the axon, but MAP2 was observed only in the 
short proximal segment of the axon (Figures 3e and 3f). 
Exogenous tau was found in the cell body and dendrites 
as well as in the axon. However, many studies investigat- 
ing the subcellular localization of tau in neurons have been 
done using TAU-1, which recognizes only the unphosphor- 
ylated form of tau at the TAU-1 site (residues 191-225; 
Figure 1 B) but does not react with the phosphorylated tau 
at this site, and it was reported that TAU-l-unreactive tau 
was detected in the cell body and dendrites (Binder et al., 
1985; Papasozomenos and Binder, 1987; Hasegawa et 
al., 1992; Szendrei et al., 1993). To investigate the phos- 
mice, stained by the anti-MAP antibodies used in this study. TAU-1 
(lane 1), a monoclonal anti-tau antibody (Binder et al., 1985), recog- 
nized tau. HM-2 (lane 2), a monoclonal anti-MAP2 antibody, stained 
both MAP2 and MAP2C. Affinity-purified rabbit anti-MAP2 antibody 
(lane 3) recognized only high molecular weight MAP2 but did not react 
with MAP2C. Monoclonal anti-MAP1B antibody (lane 4) stained high 
molecular weight MAP1B heavy chain. 
(b and c) Distribution f native MAPs in primary cultured spinal cord 
neurons 17 days after plating. Cells were double stained by TAU-1 
(b) and polyclonal anti-MAP2 antibody (c). TAU-1 stained axons (thin 
neurites) but did not react with cell bodies r d ndrites (thicker neurites) 
observed in anti-MAP2 staining. MAP2 was found in cell bodies and 
dendrites but not in axons. 
(d) In situ hybridization of spinal cord neurons probed by a ~-actin- 
specific fragment (3' untranslated region of 13-actin cDNA) to investi- 
gate the neuron-specific (or -dominant) high expression promoter. The 
expression level of ~-actin mRNA in neurons was high, whereas that 
in glial cells was low. Bar, 50 p.m. 
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Figure 3. Transfected Tau and MAP2C Were Transported Far along Axons, whereas MAP2 Was Found only in the Short Proximal Segments 
of Axons 
Immunofluorescence of primary cultured spinal cord neurons 5 days after transfection. 
(a-c) Neurons transfected with c-myc-tagged MAPs, stained with anti-c-myc antibody (a, tau; b, MAP2C; c, MAP2; insets, high magnifications)• 
(d) Compilation of lengths of entry into axons for tau, MAP2, and MAP2C. Although tau and MAP2C were transported some distance along axons 
(tau, 878 _+ 333 p,m, n = 22; MAP2C, 600 -4- 132 ~m, n = 16), MAP2 was found only in their short proximal segments (MAP2, 22.7 -4- 31.0 pm, 
n = 29). 
(e and f) Cotransfected neuron with tau(c-myc) and MAP2(c-myb), double-stained with anti-c-myc and anti-c-myb antibodies (e, tau; f, MAP2). The 
expression levels of tau and MAP2 were equalized (see Experimental Procedures). In the same neuron and at the same expression level, tau 
entered the axon, but MAP2 did not. Bar, 50 p,m. 
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phorylation state of both intrinsic and exogenous tau, we 
performed two studies: TAU-1 staining of exogenous tau 
and a dephosphorylation study on primary cultured neu- 
rons. Double staining of tau(c-myb)-transfected cells re- 
vealed that the exogenous tau, regardless of its phosphor- 
ylation state (staining by anti-c-myb antibody), was found 
in the axon, cell body, and dendrites (Figure 4a), whereas 
TAU-1 staining was strong in the axon but faint in the cell 
body and dendrites, similar to the native localization of 
tau stained by TAU-1 (Figure 2b; Figure 4b). Although 
TAU-1 also stained native tau in the axon, the staining of 
axons of transfected neurons was much stronger than that 
of untransfected neurons, meaning that this strong stain- 
ing was mostly exogenous (Figures 4b and 4c). Next, in 
the phosphatase treatment study, TAU-1 stained the cell 
body and dendrites in addition to the axon in the dephos- 
phorylated neurons, although the staining in the cell body 
and dendrites was weaker than that in the axon, and it 
tended to be restricted to the proximal dendrites (Figure 
4d). These data indicated that exogenous tau showed simi- 
lar distribution to native tau in neurons. 
Microtubule Binding of Tau Was Stronger in the 
Axon, whereas That of MAP2 Was Tighter in the 
Cell Body and Dendrites 
To examine the possible involvement of locally differing 
microtubule binding affinities of these MAPs on their differ- 
ential Iocalizations, we permeabil ized the cells in a micro- 
tubule-stabilizing buffer before fixation to remove the solu- 
ble proteins (Figure 5). Tau remained in the axon in the 
extraction condition in which most of tau in the cell body 
and dendrites disappeared (Figure 5a). By the same pro- 
cedure, however, MAP2C, which was also transported a 
sizeable distance along the axon, mostly disappeared 
from the axon, while remaining in the cell body and den- 
drites like MAP2 (Figures 5b and 5c). This indicated that 
tau bound to microtubules more strongly in the axon than 
in the cell body or dendrites, whereas MAP2/MAP2C 
bound to microtubules more tightly in the cell body and 
dendrites than in the axon. 
Figure 4. Tau Is HighlyPhosphoryiatedintheCellBodyand Dendrites 
but Not in the Axon 
(a-c) Immunofluorescence of tau(c-myb)-transfected neurons, dou- 
ble-stained with anti-c-myb antibody and TAU-1. Anti-c-myb antibody 
(a) stained all the exogenous tau, and the staining was prominent in 
the cell body and dendrites as well as in the axon. In contrast, TAU-1 
(b) stained the axon strongly, but he cell body and dendrites were 
stained very weakly. (c) shows the same picture as (b) but was printed 
differently in order to observe native tau in untransfected axons. Al- 
though TAU-1 stained both native and transfected axons, transfected 
axons were stained much stronger than native ones, suggesting that 
the strong staining of axons in the transfected neurons was mostly 
exogenous. 
(d) TAU-1 staining of primary cultured neurons after phosphatase treat- 
ment. TAU-1 recognized the cell bodies and dendrites in addition o 
axons in the phosphatase-treated neurons, although the staining in 
the cell body and dendrites is weaker than that in the axon. As TAU-1 
does not recognize phosphorylated tau at the TAU-1 site (Papasozo- 
menos and Binder, 1987), most of the intrinsic and exogenous tau 
may be phosphorylated at this site in the cell body and dendrites. Bar, 
50 ~m. 
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Figure 5. Locally Differing Microtubule Binding of Transfected Tau, 
MAP2, and MAP2C in Neurons 
Immunofluorescence of neurons transfected with tagged MAPs, per- 
meabilized before fixation to investigate their microtubule binding (a, 
tau ; b, MAP2; c, MAP2C). The staining of tau remained in the axon, 
but mostly disappeared from the cell body and dendrites. On the other 
hand, MAP2 and MAP2C were found in the cell body and dendrites, 
but not in the axon. (a) low magnification; (b and c) high magnification. 
Bar, 50 :~m. 
Domain Functions of Tau, MAP2, and MAP2C for 
Subcellular Sorting 
These studies using full-length MAPs revealed that axonal 
entry of MAP2 was less in length than that of tau or MAP2C, 
and that microtubule binding of tau was stronger in the 
axon than in the cell body and dendrites, whereas the 
binding of MAP2/MAP2C was tighter in the cell body and 
dendrites than in the axon. To study further the domain 
functions of these MAPs for their different subcellular dis- 
tribution and microtubule binding, we performed a series 
of transfection studies using chimeric/deletion mutants 
(Figure 1 ; Table 1 ; Figure 6; Figure 7). Tau-MAP2, MAP2- 
Tau, and MAP2C-Tau are chimeric mutants (e.g., Tau- 
MAP2 contains the N-terminal projection domain of tau, 
fused to the C-terminal microtubule-binding domain of 
MAP2). Tau(N), MAP2(N), and MAP2C(N) are deletion mu- 
tants containing only their N-terminal projection domains 
(e.g., Tau(N) has the N-terminal domain of tau but lacks 
its C-terminal microtubule-binding domain). Tau(MT) and 
MAP2(MT) are also deletion mutants and consist of their 
C-terminal microtubule-binding domains (e.g., Tau(MT) 
contains only the C-terminal half of tau without its N-terminal 
projection domain). 
First, we measured the entry lengths of the transfectants 
into axons. MAP2 (23 I~m) and the mutants containing the 
long N-terminal projection domain of MAP2 (MAP2-tau 
[198 p.m] and MAP2(N) [214 i~m]) were transported along 
axons for shorter distances.(Table 1; Figures 6a and 6b). 
On the other hand, tau, MAP2C, and the mutants that did 
not have the N-terminal half of MAP2 were transported 
far into axons, with no significant differences in the stained 
length among them (600-900 tim; Table 1; Figure 6c). 
To exclude the possibility that the N-terminal projection 
domain of MAP2 suppressed its entry into axons only be- 
cause of its long molecular size, we investigated the local- 
ization of intrinsic MAP1B heavy chain, which is larger in 
molecular weight and longer in molecula'r structure, and 
found it in the axon, cell body, and dendrites (Figure 6d), 
as previously reported (Sato-Yoshitake t al., 1989). 
Next, to investigate the domains for their regionally se- 
lective microtubule binding, cells were permeabilized be- 
fore fixation. Tau and the mutants containing the C-terminal 
microtubule-binding half of tau (MAP2-tau, MAP2C-tau, 
and tau(MT)) remained in the axon, whereas MAP2, 
MAP2C, and the mutants with the C-terminal domain of 
MAP2 (tau-MAP2 and MAP2(MT)) were found in the cell 
body and dendrites, but tended to disappear from axon. 
The mutants lacking the microtubule-binding domain 
(tau(N), MAP2(N), and MAP2C(N)) disappeared from the 
transfected cells (Table 1; Figure 7). 
Discussion 
J~-Actin Promoter May Work as a High Expression 
and Neuron-Selective Promoter in Primary Cultured 
Spinal Cord Cells 
In situ hybridization studies suggested that the ~-actin pro- 
moter was highly activated in neurons but was suppressed 
in glial cells in the primary cultured spinal cord (Figure 
2d). Indeed, this promoter showed a high level, neuron- 
dominant expression pattern in our transfection experi- 
ments. This study indicated that transfection using I~-actin 
enhancer-driven plasmid into primary cultured spinal cord 
neurons may be a useful and powerful tool to introduce 
cDNAs into cultured neurons. 
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Figure 6. The N-Terminal Projection Domain of MAP2 Suppresses Its Entry into Axons 
(a-c) Immunofluorescence of neurons transfected with MAP2-tau (a), MAP2(N) (b), or MAP2(MT) (c). MAP2-tau or MAP2(N), which contains the 
N-terminal domain of MAP2, were transported a shorter distance along the axon, although MAP2(MT), which contains the microtubule-binding 
domain of MAP2 but lacks its N-terminal domain, was transported far into he axon, like tau and MAP2C. 
(d) Localization of native MAP1B (heavy chain) in the primary cultured neurons. Cells were stained by monoclonal anti-MAP1 B antibody. MAP1 B, 
which is larger in molecular weight and longer in molecular structure than MAP2, was found in the axon, cell body, and dendrites in nature. (a, 
b, and d) high magnification; (c) low magnification. Bar, 50 ~.m. 
Transfected Tagged MAP2 and Tau Showed Similar 
Localizations to Native MAPs in Neurons 
Tau is abundant in the axon, whereas MAP2 is localized 
in the cell body and dendrites. MAP2C is observed in the 
cell body, dendrites, and axon of a developing neuron. 
As we used a transfection method using the constructs 
encoding MAPs and their mutants fused with a tag se- 
quence in their C-terminal end to investigate their sorting 
mechanisms, it is necessary to examine the extent of their 
effects on the subcellular localization of exogenous MAPs. 
Tagged MAP2 showed distribution similar to that of native 
MAP2; MAP2 was observed in the cell body and dendrites 
but was found only in the short proximal segment of the 
axon. In the case of MAP2C, although exogenous MAP2C 
was found in the cell bodies, dendrites, and axons, native 
MAP2C was not detected in axons by immunofluores- 
cence microscopy (Figure 3). As for tau, although exoge- 
nous tau was detected in the cell body and dendrites as 
well as in the axon by anti-tag antibody, its TAU-1 staining 
was axon-dominant  and disappeared almost completely 
from the cell body and dendrites (Figures 4a-4c). In addi- 
tion, the phosphatase treatment study revealed that TAU-1 
also stained the cell body and dendrites in dephosphory- 
lated primary cultured neurons, although the staining in 
the cell body and dendrites was much weaker than that 
in the axon (Figure 4d). Considering the fact that many of 
the studies on tau were performed using TAU-1 and that 
TAU-l -unreact ive tau is observed in the cell body and den- 
drites (Papasozomenos and Binder, 1987), we think that 
exogenous tau showed a distribution similar to that of na- 
tive tau in neurons, although the amount of exogenous 
tau in the cell body and dendrites relative to that in the 
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Table 1. Axonal Entry of Native and Mutant MAPs and Their Local Microtubule Binding 
Staining after Extraction 
Staining of Axons 
without Extraction (~m) Cell Body Dendrites Axon 
tau 878 ± 333 (n = 22) - - + 
MAP2 23 ± 31 (n = 29) + + ' - 
MAP2C 600 ± 132 (n = 16) + + - 
tau-MAP2 663 _+ 233 (n = 26) + + - 
MAP2-tau 198 _+ 103 (n = 21) - - + 
MAP2C-tau 875 ± 288 (n = 38) - - + 
tau(N) 901 ± 292 (n = 23) - - - 
MAP2(N) 214 ± 187 (n = 12) - - - 
MAP2C(N) 886 ± 181 (n = 25) - - - 
tau(MT) 708 _+ 214 (n = 35) - - + 
MAP2(MT) 595 _+ 317 (n = 39) + + - 
Entry length measurements: MAP2 (-23 I~m) and the mutants containing its N-terminal projection domain (MAP2-tau and MAP2(N), -200 p.m) 
were not transported as far along the axon as the others (600-900 p.m). Microtubule binding: When cells were permeabilized before fixation, the 
mutants containing the C-terminal binding half of tau (MAP2-tau, MAP2C-tau, and tau(MT)) remained in axons, whereas those with the C-terminal 
half of MAP2 (tau-MAP2 and MAP2(MT)) were observed in cell bodies and dendrites. The mutants lacking the microtubule-binding domain (tau(N), 
MAP2(N), and MAP2C(N)) disappeared from the cells. Staining remained (+) or disappeared (-) after extraction. 
axon is somewhat higher than it is with native tau. As for 
the distribution of exogenous MAP2C in the axon and tau 
in the cell body and dendrites, we think that it may be due 
to the higher amount of expression of these MAPs. Indeed, 
in neurons at an early developmental  stage, when their 
expression levels are higher, MAP2C is reported to be 
found in the cell body, dendrites, and axon (Tucker et al., 
1988a). Thus, we believe that the inserted sequence and 
the overexpression by transfection did not change their 
physiological distributions significantly. 
N-Terminal Projection Domain of MAP2 Interferes 
with Its Axonal Transit 
As for the axonal distribution of transfected MAPs, tau and 
MAP2C were found far into the axon ( -  900 I~m), whereas 
MAP2 was observed only in the short proximal segment 
( -23  ~m; Figure 3). To investigate this differing axonal 
transit among these MAPs, we performed mutant studies 
and showed that the mutants, MAP2-tau and MAP2(N), 
containing the long N-terminal projection domain of MAP2, 
were found to be transported a lesser length in axons 
( -  200 i~m) than the others ( -  900 I~m). This suggests that 
the N-terminal projection domain of MAP2, especially the 
inserted region lacking in MAP2C, suppressed its axonal 
transit in neurons. The axonal distribution of MAP1 B heavy 
chain, a larger molecule than MAP2, indicated that this 
inhibition may not be due only to its larger protein size 
(Table 1; Figure 6). However, considering the fact that 
MAP2 was transported along the axon a much shorter 
distance (23 I~m) than MAP2-tau or MAP2(N) ( -200  I~m) 
and that MAP2 bound to microtubules more tightly than 
MAP2-tau or MAP2(N) in the cell body and dendrites, 
other mechanisms (e.g., locally selective microtubule 
binding) may also keep MAP2 within the cell body and 
dendrites, preventing its entry into the axon, in addition 
to the suppression of axonal transit by MAP2's N-terminal 
projection domain. 
Microtubule-Binding Domains of Tau and MAP2 
Determine Their Locally Selective 
Microtubule-Binding Abilities 
Tau and MAP2/MAP2C share a homologous microtubule- 
binding domain (Figure 1) (Aizawa et al., 1988; Lee et al., 
1988; Goedert et al., 1989; Kanai et al., 1989; Kosik et 
al., 1989; Lewis et al., 1989; Papandrikopoulou et al., 
1989), and they compete with each other in microtubule 
binding in vitro (Kim et al., 1986). in vivo studies using 
nonneuronal cells also revealed that Sf9 cells cotrans- 
fected with tau and MAP2 projected one or more pro- 
cesses, but both MAPs were colocalized in the cell body 
and in the processes (Chen et al., unpublished data). 
These data suggest that tau binds to microtubules just 
like MAP2/MAP2C in vitro and in vivo. However, their mi- 
crotubule-binding properties were quite different in neu- 
rons; tau bound to microtubules more strongly in the axon 
than in the cell body and dendrites, whereas MAP2/ 
MAP2C bound to microtubules more tightly in the cell body 
and dendrites than in the axon, and these region-selective 
bindings were determined by their C-terminal microtubule- 
binding regions (Figure 5; Table 1 ; Figure 7). This suggests 
that microheterogeneity in the microtubule-binding do- 
main between tau and MAP2 (Figure 1 B) determines their 
locally differing binding properties in neurons, and we think 
that this region-selective microtubule binding could deter- 
mine their locally differing turnover rates (Okabe and Hire- 
kawa, 1989; Hirokawa et al., unpublished data) and may 
work as one of the sorting mechanisms for these MAP& 
Microtubule Binding of Tau May Be Regulated by 
Locally Selective Phosphorylation 
What regulates the locally differing microtubule bindings 
of tau and MAP2/MAP2C? Our data suggest that phos- 
phorylation may be involved in this mechanism, as 
transfected tau in the cell body and dendrites was mostly 
phosphorylated at the TAU-1 site, but not in the axon (Fig- 
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phosphorylated at Ser(Thr) residues followed by Pro than 
adult tau (Geedert et al., 1993; Watanabe et al., 1993). In 
addition, in vitro studies revealed that several proline- 
directed kinases (e.g., cdc2 kinase, tau protein kinases, 
MAP kinase, and MAP2 kinase) phosphorylate tau into a 
TAU-l-unreactive form, which is reduced in microtubule 
polymerization and binding (Ishiguro et al., 1991; Drewes 
et al., 1992; Gustke et al., 1992; Ishiguro et al., 1992a, 
1992b; Ledesma et al., 1992; Vulliet et al., 1992; Arioka 
et al., 1993; Lu et al., 1993; Scott et al., 1993). Thus, it 
is possible that the selective binding of tau to axonal micro- 
tubules may be regulated by phosphorylation, which con- 
tributes to its axonal accumulation; once tau is expressed 
in the cell body, it is phosphorylated (TAU-l-unreactive 
form) and reduced in its microtubule-binding ability. Phos- 
phorylated tau in the cell body and dendrites can be loaded 
on the transport system into the axon, where tau is dephos- 
phorylated and can bind to microtubules more tightly 
(TAU-l-reactive form). 
Figure 7. Microtubule-Binding Domains of Tau and MAP2 Determine 
Their Locally Differing Microtubule Binding 
Immunofluorescence of neurons transfected with tau(MT) (a), 
MAP2(MT) (b), or tau(N) (c), permeabilized before fixation toinvesti- 
gate their microtubule binding. The staining of tau(MT) (a) remained 
in the axon but mostly disappeared from the cell body and dendrites. 
On the other hand, MAP2(MT) (b) was found in the cell body and 
dendrites but not in the axon. Tau(N) (c), which lacks the microtubule- 
binding domain, disappeared f om the cells. (a) Low magnification; (b 
and c) high magnification. Bar, 50 p.m. 
ure 4). The TAU-1 site contains several Ser(Thr)Pro motifs 
(Kosik et al., 1988; Biernat et al., 1992; Szendrei et al., 
1993), and juvenile tau, which is often found in the cell 
body and dendrites as well as in the axon, is much more 
Proline-Directed Kinase(s) May Regulate Protein 
Behavior in the Axon versus the Cell Body and 
Dendrites in Neurons 
Although proline-directed protein phosphorylation is rele- 
vant to the somatic ell cycle, its function in cells of differ- 
entiated states is not well known (Hall and Vulliet, 1991; 
Plech and Sanghera, 1992). Considering the transfected 
tau as the substrate for proline-directed kinases, the bal- 
ance between kinase and phosphatase activities may be 
kinase-dominant in the cell body and dendrites but phos- 
phatase-dominant in the axon. Besides the regulation of 
tau in microtubule binding by phosphorylation, adequate 
phosphorylation is necessary for MAP2 to bind to microtu- 
bules (Brugg and Matus, 1991), and there is a report that 
proline-directed kinases can be involved in this phosphory- 
lation as well (Roll et al., 1993, Am. Soc. Cell Biol., ab- 
stract). These results suggest that proline-directed kinase 
may play an important role for the neuronal polarity. MAP2 
and MAP2C may also be regulated by proline-directed 
phosphorylation i neurons, although its effects on micro- 
tubule binding are quite opposite; MAP2 and MAP2C are 
phosphorylated in the cell body and dendrites to bind to 
microtubules more tightly, but they are reduced if they are 
dephosphorylated in axons. 
Sorting Mechanisms of Tau and MAP2 in Neurons 
The mechanisms underlying the sorting of tau and MAP2 
in neurons are likely to be complex. The present study 
clearly showed the decreased transit of MAP2 into the 
axon caused by its N-terminal projection domain. This re- 
sult seemingly contradicts our previous microinjection 
study of biotinylated MAP2 into cultured motor neurons, 
which demonstrated that microinjected biotin-MAP2 was 
transported along the axon for a certain distance (Okabe 
and Hirokawa, 1989). However, other studies have shown 
that, biochemically, MAP2 exists in white matter, although 
in lesser amounts (Vallee, 1982), immunocytochemically, 
MAP2 is localized in small amounts in the ax0n (Hirokawa 
etal., 1985; Papasozomenos et al., 1985), and our unpub- 
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l ished im m unoblot  f nd ngs revealed the ex is tence of smal l  
amounts  of  MAP2 in per ipheral  nerves (H i rokawa et al., 
unpubl ished data). Therefore,  it is reasonab le  to conc lude 
that MAP2 is actual ly t ransported into axons  in vivo, al- 
though the amount  is smal l  compared  with other  MAPs  
such as tau. One of the reasons  for the t ransport  of a 
lesser amount  of  MAP2 is due to the suppress ion  of  MAP2 
entry into axon  by its N-terminal  project ion domain,  as 
shown in this study. In addit ion, the rapid turnover  of MAP2 
in the axon,  demonst ra ted  in our prev ious microin ject ion 
study, could a lso contr ibute to the lesser  ex is tence of 
MAP2 in axon (Okabe and Hi rokawa,  1989). 
However ,  based  on prev ious studies and the present  
results, it is reasonab le  to conc lude that there may be 
several  mechan isms that cause  the se lect ive local izat ion 
of tau in the axon and MAP2 in the dendr i tes  in vivo. First 
is the extended local izat ion of  mRNA encod ing  MAP2 in 
the dendr i tes (Garner  et al., 1988) and mRNA encod ing 
tau in the initial port ion of  the axon (L i tman et al., 1993), 
second is the locally di f fer ing microtubule-b ind ing affini- 
t ies of  MAP2 and tau (Okabe and Hi rokawa,  1989; Hiro- 
kawa et al., unpubl ished data  and present  study), third is 
the select ive stabi l izat ion of  MAP2 in dendr i tes  (Okabe 
and Hirokawa,  1989) and tau in the axon (H i rokawa et al., 
unpubl ished data), and fourth is the decreased  transit  of 
MAP2 into the axon  (present study). These  di f ferent  mech-  
an isms in concert  could contr ibute to the f inal select ive 
local izat ion of MAP2 and tau. How the project ion domain  
of  MAP2 in f luences the mechan isms remains  to be deter- 
mined. 
Experimental Procedures' 
Antibodies 
Mouse monoclonal anti-c-myc antibody (Mycl-9E10; Evan et al, 1985; 
Wong and Cleveland, 1990) and sheep polyclonal anti-c-myb antibody 
were from Cambridge Res, Biochem. Ltd. (England). TAU-1, a mouse 
monoclonal antibody against tau, was from Boehringer Mannheim 
(Germany; Binderet aL, 1985). Mouse monoclonal anti-MAP2 antibody 
(HM-2) was purchased from Sigma Chem. Co., and affinity-purified 
polyclonal anti-MAP2 antibody (Hirokawa et al., 1988a) was a gener- 
ous gift from Dr; Y. Ihara (Tokyo Univ.). Mouse monoclonal anti-MAP1 B 
antibody was previously described (Sato-Yoshitake t al., 1989). Rho- 
damine-conjugated goat anti-mouse IgG, fluorescein-conjugated goat 
anti-rabbit IgG, and fluorescein-conjugated donkey anti-sheep IgG 
were from Chemicon International, Inc. All antibodies were diluted 1 : 
100 in an antibody buffer. 
Immunoblot 
Postnatal 0 day (P0) mouse brains were homogenized in buffer A (100 
mM PIPES, 1 mM MgCI2, 1 mM EGTA, 0.5 mM phenylmethylsulfonyl 
fluoride, 10 pm/ml leupeptin). The homogenate was centrifuged at 
10,000 x gfor90 minat2'°C.SDS-polyacrylamidegelelectrophoresis 
(SDS-PAGE) of the "resulting crude homogenate was carried out on 
a 7.5% gel according to the method of Laemmli (1970). The bands were 
electrophoretically transferred to nitrocellulose paper, and immunoblot 
was performed by the standard procedu[e. 
Cell Culture 
Spinal cord neurons werecultured according to the method of Ransom 
et al. (1977) with slight modifications. Spinal cords were taken from 
12- to 14-day-old mouse embryos, treated with 0.1% trypsin for 15 
rnin at 37°C, and idissociated by repeated passage through a pipette. 
The cell suspehsi()ns were plated onto polylysine-treated coverslips 
and maintained in Dulbecco's modified Eagle's medium supplemented 
with 5% (vol/vol) precolostrum newborn calf serum (MitsubJshi Chemi- 
cal Industries, Tokyo) and 5% (vol/vol) horse serum (GIBCO). 
RNA Probes for In Situ Hybridization 
The mouse ~-actin probe clone pSPMbA-3'ut, kindly provided by Dr. 
S. Sakiyama (Tokunaga et al., 1986), contains the sequence encoding 
the 3' noncoding region of ~-actin cDNA (about 80 bp) in a pGEM-1 
vector. Digoxygenin-labeled single-strand RNA probes in the anti- 
sense or sense orientation were synthesized from linearized templates 
using the appropriate bacterial polymerase (Sp6 or T7 RNA polymer- 
ases) in the presence of digoxygenin UTP (Boehringer Mannheim) as 
described by the manufacturer. 
In Situ Hybridization 
Cells grown on coverslips were fixed for 20 rain by 2% paraformalde- 
hyde, 0.1% glutaraldehyde in 0.1 M phosphate buffer (pH 7.2), and 
then incubated successively in 0.3% Triton X-100 in phosphate- 
buffered saline (PBS) for 5 min, in 0.2 M HCI for 20 min, in 20 p.g/ml 
proteinase K (Sigma) in 50 mM Tris (pH 7.5) containing 2 mM CaCI2 
for 10 min, in 4% paraformaldehyde in PBS for 5 rain, twice in 0.2% 
glycine in PBS for 30 min, and in 50% formamide in 2 x SSC for 1 hr. 
Hybridization was carried out overnight at 42°C in hybridization 
buffer (0.1 mg/ml salmon sperm DNA, 0.2 mg/ml tRNA, 10% dextran- 
sulfate, 50% formamide, 5x  SSC, 1 x Denhardt's solution, 100 ~g/ 
ml heparin, 10 mM dithiothreitol) containing RNA probe. Cells were 
washed in 4× SSC at 42°C for 20 min and in R buffer (10 mM Tris 
[pH 7.5], 0.5 M NaCI) at 37°C for 15 rain and then treated with RNase 
A (20 i~g/ml) in R buffer at 37°C for 45 min. Cells were washed twice 
in R buffer for 15 rain, in 2 x SSC at 50°C for 1 hr, and twice in 0.1 x 
SSC at 50°C for 1 hr. Cells were incubated for 30 rain at 37°C with 
anti-digoxygenin antibody (conjugated to alkaline phosphatase) di- 
luted 1:1000 (Boehringer Mannheim). At the end of the reaction, cells 
were washed three times for 15 rain each at room temperature with 
PBS, equilibrated for 5 rain in buffer containing 100 mM Tris (pH 9.5), 
100 mM NaCI, and 50 mM MgCI2, and developed with nitroblue tetrazo- 
lium-bromochloroindolyl phosphate solution (0.34 mg/ml nitroblue tet- 
razolium and 0.175 mg/ml bromochloroindolyl phosphate in the same 
buffer) at room temperature. 
Construction of Tagged MAPs and Their Mutants 
For making the chimeric/deletion mutants, we determined the border 
between the N-terminal projection domain and the C-terminal microtu- 
bule-binding half at the 162nd residue of tau, as the following sequence 
(162-369) is necessary for tau to bind to microtubules in vivo (Kanai 
et al., 1992). Since tau has a BamHI site at this residue, another BamHI 
site was introduced to the corresponding residue in MAP2 (1586) or 
MAP2C (225) to make chimeric mutants. MAP2 cDNA was a generous 
gift from N. J. Cowan (New York Univ.). A short sequence from c-myc 
(KLISEEDL) or c-myb (EDPEKEKRIKEL) was fused to the C-terminal 
tail of full-length MAPs and their mutants as a tag. The addition of 
tags, making of deletion mutants, and introduction of BamHI sites were 
performed by polymerase chain reaction (PCR). All the PCR fragments 
were sequenced and then inserted into a 13-actin enhancer-driven 
plasmid for the transfection studies. 
Transfection 
The constructs we re transfected into primary cultu red neurons 12 days 
after plat!ng by the standard calcium phosphate technique (Xie, 1984; 
Kanai et al., 1989, 1992). A 0.5 ml calcium phosphate precipitate sus- 
pension containing 1 I~g of expression construct was added to a 3.5 
cm dish incubated with primary cultured neurons. After 4 hr, the culture 
was fed fresh medium, and after certain periods, the culture was pre- 
pared for observation by light microscopy. The transfection efficiency 
was about 2%-5%. 
Immunofluorescence 
Cells were fixed for 15 rain at 37°C with 2% paraformaldehyde, 0.1% 
glutaraldehyde in PEM buffer (S0 mM PIPES, 1 mM MgCI2, 1 mM 
EGTA) directly or in a microtubule-stabilizing buffer (80 mM PIPES, 
1 mM MgCI2, 1 mM EGTA, 10 pM Taxol, 1 mM GTP [pH 6.6]) after 
extraction for 2 rain at 37°C with 0.2% Triton ×-100 in the same buffer. 
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Cells were then permeabilized with 1% Triton X-100 in PBS and treated 
with 1 mg/ml NaBH, in PBS to quench the glutaraldehyde. In the phos- 
phatase treatment study, cells were incubated with 20 U/ml calf intes- 
tine alkaline phosphatase (TOYOBO, Japan) in alkaline phosphatase 
buffer (50 mM Tris; pH 8.0) at 37°C for 2 hr (Papasozomenos and 
Binder, 1987; Kanai et al., 1989). 
The cells were reacted sequentially with a monoclonal anti-c-myc 
antibody alone or together with a polyclonal anti-c-myb antibody for 
the first antibodies, and rhodamine-conjugated goat anti-mouse IgG 
alone or together with fluorescein-conjugated onkey anti-sheep IgG 
for the second antibodies. The cells were examined with a Zeiss Axle- 
photo 14 epifluorescence microscope. 
To equalize the expression levels of tau and MAP2 in the cotransfec- 
tion studies, we determined the cDNA ratio of tau to MAP2 by doing 
pairs of cotransfections: tau(c-myc)lMAP2(c-myb) and MAP2(c-myc)l 
tau(c-myb) (Figures 3e and 3f). Their immunofluorescence intensities 
were monitored with an image processor (ARGUS-100; Hamamatsu 
Photonics, Shizuoka, Japan; Kanai et al., 1992). When the intensity 
ratios of c-myc to c-myb were the same between the pair, the expressed 
amount of tau was equal to that of MAP2. 
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